French Ipsen Acquires Kartos Therapeutics for $450 Million

French biotechnology company Ipsen has signed an agreement to acquire private biotech firm Kartos Therapeutics for $450 million. The acquisition is seen as part of Ipsen's strategy to strengthen its oncology portfolio. Under the deal, Ipsen will purchase Kartos Therapeutics' shares in cash. The acquisition is expected to close in the first quarter of 2024. Kartos Therapeutics focuses on drug development for hematologic cancers and solid tumors. Through this acquisition, Ipsen will gain access to Kartos Therapeutics' lead candidate, a JAK inhibitor used in the treatment of myelofibrosis. Additionally, the company's other early-stage projects will be integrated into Ipsen's R&D pipeline. Analysts note that this deal will contribute to Ipsen's growth targets in oncology. The $450 million purchase price is considered manageable given Ipsen's cash position and borrowing capacity. This is not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 60%

The news is about a biotech acquisition that does not directly affect GOOGL, so a neutral impact is expected. Technical indicators point to weakness: RSI at 33 is near oversold territory, MACD is below zero and below its signal line, and the price is below both the 20-day and 50-day moving averages. A 2.9% decline in the last 24 hours confirms short-term selling pressure. However, the RSI approaching oversold territory also raises the possibility of a rebound. Given the directional uncertainty, a neutral view is more appropriate.

RSI 14

33.4

MACD

-3.02

24h Δ

-2.89%

Canlı Grafikler